THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS
Identifieur interne : 000316 ( Istex/Curation ); précédent : 000315; suivant : 000317THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS
Auteurs : David Scott [Royaume-Uni] ; David Scott [Royaume-Uni] ; Paul Bacon [Royaume-Uni]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 1982-08.
English descriptors
- Teeft :
- Acute phase proteins, Acute phase response, Adverse reactions, Annals, Antiinflammatory drugs, Arthritis, Aspirin, Bladder toxicity, Blood dyscrasias, Clinical benefits, Clinical practice, Clinical response, Clinics committee, Considerable debate, Conventional drugs, Crockson, Cyclophosphamide, Cytotoxic, Cytotoxic drugs, Disease activity, Dos, Drug treatment, England journal, Further studies, High levels, Individual patient, Joint damage, Late side effects, Mcconkey, Medical journal, Myasthenia gravis, Newer drugs, Nonsteroidal drugs, Nsaid, Other drugs, Other workers, Penicillamine, Prospective studies, Prostaglandin, Prostaglandin synthesis, Radiological changes, Recent years, Rheumanc diseases, Rheumatic, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid disease, Rheumatoid factor, Secondline drugs, Serum protein, Severe disease, Side effects, Significant problem, Similar effects, Steroid, Wide variety.
Abstract
Anti‐rheumatic drugs used in rheumatoid arthritis fall into two distinct groups: non‐steroidal anti‐inflammatory and second‐line drugs. Non‐steroidal anti‐inflammatory drugs give early symptomatic improvement and reduce the degree of acute inflammatory synovitis. Second‐line drugs such as gold or D penicillamine exert an anti‐inflammatory effect only after two to three months and act by suppressing disease activity: these reduce the ESR and other acute phase responses. However, the evidence that any of these drugs halt the progression of radiological changes or can be used as long‐term agents to control the disease over a period of years is weak. The current use of anti‐rheumatic drugs follows a general pattern with nonsteroidal anti‐inflammatory drugs used alone in patients with mild disease, whereas patients with severe disease also receive second‐line drugs. As yet the long‐term effect of this policy is not known. Cytotoxic drugs should be restricted to patients with severe disease who either fail to respond to conventional second‐line drugs or have active extra‐articular disease, particularly those with vasculitis.
Url:
DOI: 10.1111/j.1365-2710.1982.tb01027.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000316
Links to Exploration step
ISTEX:A2819C623247D858C1AD34449388A5AAE39F5705Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS</title><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name><affiliation wicri:level="1"><mods:affiliation>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea></affiliation></author><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name><affiliation wicri:level="1"><mods:affiliation>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea></affiliation></author><author><name sortKey="Bacon, Paul" sort="Bacon, Paul" uniqKey="Bacon P" first="Paul" last="Bacon">Paul Bacon</name><affiliation wicri:level="1"><mods:affiliation>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea></affiliation><affiliation><mods:affiliation>Correspondence address: Professor P. A. Bacon.</mods:affiliation><wicri:noCountry code="no comma">Correspondence address: Professor P. A. Bacon.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A2819C623247D858C1AD34449388A5AAE39F5705</idno><date when="1982" year="1982">1982</date><idno type="doi">10.1111/j.1365-2710.1982.tb01027.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-2P6NCG92-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000316</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000316</idno><idno type="wicri:Area/Istex/Curation">000316</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">THERAPEUTIC PROGRESS—REVIEW VI*TREATMENT OF RHEUMATOID ARTHRITIS</title><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name><affiliation wicri:level="1"><mods:affiliation>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea></affiliation></author><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name><affiliation wicri:level="1"><mods:affiliation>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea></affiliation></author><author><name sortKey="Bacon, Paul" sort="Bacon, Paul" uniqKey="Bacon P" first="Paul" last="Bacon">Paul Bacon</name><affiliation wicri:level="1"><mods:affiliation>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea></affiliation><affiliation><mods:affiliation>Correspondence address: Professor P. A. Bacon.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">7</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="217">217</biblScope><biblScope unit="page" to="229">229</biblScope><biblScope unit="page-count">13</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1982-08">1982-08</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute phase proteins</term><term>Acute phase response</term><term>Adverse reactions</term><term>Annals</term><term>Antiinflammatory drugs</term><term>Arthritis</term><term>Aspirin</term><term>Bladder toxicity</term><term>Blood dyscrasias</term><term>Clinical benefits</term><term>Clinical practice</term><term>Clinical response</term><term>Clinics committee</term><term>Considerable debate</term><term>Conventional drugs</term><term>Crockson</term><term>Cyclophosphamide</term><term>Cytotoxic</term><term>Cytotoxic drugs</term><term>Disease activity</term><term>Dos</term><term>Drug treatment</term><term>England journal</term><term>Further studies</term><term>High levels</term><term>Individual patient</term><term>Joint damage</term><term>Late side effects</term><term>Mcconkey</term><term>Medical journal</term><term>Myasthenia gravis</term><term>Newer drugs</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Other drugs</term><term>Other workers</term><term>Penicillamine</term><term>Prospective studies</term><term>Prostaglandin</term><term>Prostaglandin synthesis</term><term>Radiological changes</term><term>Recent years</term><term>Rheumanc diseases</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid disease</term><term>Rheumatoid factor</term><term>Secondline drugs</term><term>Serum protein</term><term>Severe disease</term><term>Side effects</term><term>Significant problem</term><term>Similar effects</term><term>Steroid</term><term>Wide variety</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anti‐rheumatic drugs used in rheumatoid arthritis fall into two distinct groups: non‐steroidal anti‐inflammatory and second‐line drugs. Non‐steroidal anti‐inflammatory drugs give early symptomatic improvement and reduce the degree of acute inflammatory synovitis. Second‐line drugs such as gold or D penicillamine exert an anti‐inflammatory effect only after two to three months and act by suppressing disease activity: these reduce the ESR and other acute phase responses. However, the evidence that any of these drugs halt the progression of radiological changes or can be used as long‐term agents to control the disease over a period of years is weak. The current use of anti‐rheumatic drugs follows a general pattern with nonsteroidal anti‐inflammatory drugs used alone in patients with mild disease, whereas patients with severe disease also receive second‐line drugs. As yet the long‐term effect of this policy is not known. Cytotoxic drugs should be restricted to patients with severe disease who either fail to respond to conventional second‐line drugs or have active extra‐articular disease, particularly those with vasculitis.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000316 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000316 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:A2819C623247D858C1AD34449388A5AAE39F5705
|texte= THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS
}}
| This area was generated with Dilib version V0.6.33. |  |